SG11202006378PA - Humanized and de-immunized antibodies - Google Patents
Humanized and de-immunized antibodiesInfo
- Publication number
- SG11202006378PA SG11202006378PA SG11202006378PA SG11202006378PA SG11202006378PA SG 11202006378P A SG11202006378P A SG 11202006378PA SG 11202006378P A SG11202006378P A SG 11202006378PA SG 11202006378P A SG11202006378P A SG 11202006378PA SG 11202006378P A SG11202006378P A SG 11202006378PA
- Authority
- SG
- Singapore
- Prior art keywords
- humanized
- immunized antibodies
- immunized
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154427.1A EP3521308B1 (en) | 2018-01-31 | 2018-01-31 | Humanized and de-immunized antibodies |
| PCT/EP2019/052100 WO2019149689A1 (en) | 2018-01-31 | 2019-01-29 | Humanized and de-immunized antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006378PA true SG11202006378PA (en) | 2020-08-28 |
Family
ID=61132161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006378PA SG11202006378PA (en) | 2018-01-31 | 2019-01-29 | Humanized and de-immunized antibodies |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12043659B2 (ru) |
| EP (1) | EP3521308B1 (ru) |
| JP (1) | JP7337077B2 (ru) |
| KR (1) | KR20200116095A (ru) |
| CN (1) | CN111670196A (ru) |
| AU (1) | AU2019214280A1 (ru) |
| BR (1) | BR112020015194A2 (ru) |
| CA (1) | CA3088606A1 (ru) |
| EA (1) | EA202091629A1 (ru) |
| IL (1) | IL276101B1 (ru) |
| MX (1) | MX2020007986A (ru) |
| SG (1) | SG11202006378PA (ru) |
| WO (1) | WO2019149689A1 (ru) |
| ZA (1) | ZA202004784B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113957095A (zh) * | 2021-10-22 | 2022-01-21 | 江苏集萃药康生物科技股份有限公司 | 一种用于构建阿尔兹海默症动物模型的构建方法及其核酸组合物和应用 |
| WO2024107683A1 (en) * | 2022-11-17 | 2024-05-23 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA ANTIBODIES, DOSES, AND USES THEREOF |
| WO2024133925A1 (en) | 2022-12-22 | 2024-06-27 | Bioarctic Ab | Antibody which binds to abetape3 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5981830A (en) | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| CN1918131B (zh) | 2004-02-05 | 2011-05-04 | 前体生物药物股份公司 | 谷氨酰胺酰基环化酶抑制剂 |
| JP5599614B2 (ja) | 2006-11-09 | 2014-10-01 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| WO2008055947A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| DK2118101T3 (da) | 2007-03-09 | 2013-01-02 | Probiodrug Ag | IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer |
| EP2146968B1 (en) | 2007-04-18 | 2015-09-23 | Probiodrug AG | Urea derivatives as glutaminyl cyclase inhibitors |
| WO2008128982A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors |
| DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
| EP2142515B1 (en) | 2007-04-18 | 2014-03-26 | Probiodrug AG | Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors |
| JP5675340B2 (ja) | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | 新規阻害剤 |
| DK2160380T3 (da) | 2007-04-18 | 2014-06-30 | Probiodrug Ag | Cyano-guanidin derivater som glutaminyl cyclase inhibitorer |
| JP5676249B2 (ja) | 2007-04-20 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体 |
| NZ583799A (en) | 2007-09-12 | 2011-12-22 | Probiodrug Ag | Transgenic mice comprising a DNA transgene encoding ABeta peptide |
| EP3338795A1 (en) | 2008-07-21 | 2018-06-27 | Probiodrug AG | Diagnostic antibody assay |
| JP5707327B2 (ja) | 2008-09-04 | 2015-04-30 | プロビオドルグ エージー | 新規の阻害剤 |
| US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
| EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| BR112012022478B1 (pt) | 2010-03-10 | 2021-09-21 | Probiodrug Ag | Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| CN108218849B (zh) | 2013-03-15 | 2022-03-01 | 维沃永治疗公众有限公司 | 新的抑制剂 |
| NZ739181A (en) | 2015-07-16 | 2023-05-26 | Vivoryon Therapeutics N V | Anti-pyroglutamated amyloid beta humanized antibodies |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
-
2018
- 2018-01-31 EP EP18154427.1A patent/EP3521308B1/en active Active
-
2019
- 2019-01-29 SG SG11202006378PA patent/SG11202006378PA/en unknown
- 2019-01-29 EA EA202091629A patent/EA202091629A1/ru unknown
- 2019-01-29 AU AU2019214280A patent/AU2019214280A1/en active Pending
- 2019-01-29 KR KR1020207021877A patent/KR20200116095A/ko not_active Application Discontinuation
- 2019-01-29 IL IL276101A patent/IL276101B1/en unknown
- 2019-01-29 BR BR112020015194-7A patent/BR112020015194A2/pt unknown
- 2019-01-29 CN CN201980011104.3A patent/CN111670196A/zh active Pending
- 2019-01-29 CA CA3088606A patent/CA3088606A1/en active Pending
- 2019-01-29 US US16/964,892 patent/US12043659B2/en active Active
- 2019-01-29 MX MX2020007986A patent/MX2020007986A/es unknown
- 2019-01-29 JP JP2020541707A patent/JP7337077B2/ja active Active
- 2019-01-29 WO PCT/EP2019/052100 patent/WO2019149689A1/en active Application Filing
-
2020
- 2020-07-31 ZA ZA2020/04784A patent/ZA202004784B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202004784B (en) | 2021-09-29 |
| JP2021512100A (ja) | 2021-05-13 |
| JP7337077B2 (ja) | 2023-09-01 |
| MX2020007986A (es) | 2020-09-09 |
| IL276101A (en) | 2020-08-31 |
| AU2019214280A1 (en) | 2020-07-23 |
| US20210032315A1 (en) | 2021-02-04 |
| IL276101B1 (en) | 2024-09-01 |
| WO2019149689A1 (en) | 2019-08-08 |
| BR112020015194A2 (pt) | 2020-12-29 |
| EA202091629A1 (ru) | 2020-09-23 |
| EP3521308C0 (en) | 2024-03-13 |
| CA3088606A1 (en) | 2019-08-08 |
| CN111670196A (zh) | 2020-09-15 |
| EP3521308A1 (en) | 2019-08-07 |
| US12043659B2 (en) | 2024-07-23 |
| KR20200116095A (ko) | 2020-10-08 |
| EP3521308B1 (en) | 2024-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004494B (en) | Anti-tmprss2 antibodies and antigen-binding fragments | |
| IL269593A (en) | Anti-ILT4 antibodies and antigen-binding fragments | |
| IL275737A (en) | Variant antibodies against TIGIT | |
| IL283812A (en) | Humanized antibody against human pd–1 | |
| IL275734B (en) | Anti-pd-l1 antibodies and uses thereof | |
| IL282756A (en) | Humanized antibodies against SIRPα | |
| IL281272A (en) | Humanized antibodies against C5 and their uses | |
| IL280757A (en) | Monoclonal antibodies against human TIM-3 | |
| HUE059732T2 (hu) | Humanizált Clever-1 elleni antitestek és alkalmazásuk | |
| IL286690A (en) | Antibodies against egfrviii and antigen-binding fragments thereof | |
| ZA202004784B (en) | Humanized and de-immunized antibodies | |
| IL282708A (en) | Anti-tim-3 antibodies and their use | |
| IL282707A (en) | Anti-tim-3 antibodies and their use | |
| IL281608A (en) | Antibodies against human CD45RC and their use | |
| SG11202103095RA (en) | Anti-human vsig4 antibodies and uses thereof | |
| IL279355A (en) | Antigen binding protein against STEAP1 | |
| IL277296A (en) | Antibodies against PFRH5 and their antigen-binding fragments | |
| ZA202101668B (en) | Humanized anti-vegfr2 single-chain antibody and use thereof | |
| GB201911211D0 (en) | Monoclonal antibodies against ambra-1 | |
| GB201820006D0 (en) | Humanised anti-IL17BR antibody | |
| GB201820334D0 (en) | Antibodies and their uses |